

DAFTAR PUSTAKA

- Akbayram, S., Do, M., Akgün, C., Peker, E., Say, R., Aktar, F., *et al.*, 2011. Clinical features and prognosis with Guillain-Barré syndrome. *Ann Indian Acad Neurol.* 14: 98-102
- Barzegar, M., Toopchizadeh, V., Maher, M.H.K., Sadeghi, P., Jahanjoo, F., Pishgahi, A., 2017. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. *Pediatr. Res.* 82: 333–339.
- Bellanti, J.A., Escobar- Guterrez, A., Tsokos, G.C., editors. 2012. *Immunology IV: Clinical Application in Health and Disease*. 4th ed., I Care Press, Bethesda MD.
- Dias-Tosta, E., Kückelhaus, C.S., 2002. Guillain barré syndrome in a population less than 15 years old in Brazil. *Arq. Neuropsiquiatr.* 60: 367–373.
- Doets, A.Y., Jacobs, B.C., van Doorn, P.A., 2018. Advances in management of Guillain-Barré syndrome. *Curr. Opin. Neurol.* 31: 541–550.
- Doorn, P.A. Van, 2013. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). *Presse Med.* 42: e193–e201.
- Dourado Júnior, M.E.T., Fernandes, U.T., Ramos, E.S., Vital, A.L.F., Urbano, J.C.C., Queiroz, J.W., *et al.*, 2018. Egos has a reduced capacity to predicts GBS prognosis in Northeast Brazil. *Acta Neurol. Scand.* 138: 459–462.
- Draak, T.H.P., Gorson, K.C., Vanhoutte, E.K., van Nes, S.I., van Doorn, P.A., Cornblath, D.R., *et al.* , 2016. Does ability to walk reflect general functionality in inflammatory neuropathies? *J. Peripher. Nerv. Syst.* 21: 74–81.
- Filler, G., Lipshultz, S.E., 2012. Why multidisciplinary clinics should be the standard for treating chronic kidney disease. *Pediatr Nephrol.* 27 : 1831–34.
- González-suárez, I., Sanz-gallego, I., Javier, F., Rivera, R. De, Arpa, J., 2013. Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases 2–7. *BMC Neurol.* 13:95.

- Koningsveld, R. Van, Steyerberg, E.W., Hughes, R.A.C., Swan, A. V, Doorn, P.A. Van, Jacobs, B.C., 2000. Articles A clinical prognostic scoring system for Guillain-Barré syndrome. *Lancet Neurol*.6: 589–94.
- Kumar, M., Aroor, S., Mundkur, S., Kumar, S., 2015. Guillain-Barré syndrome: A clinical study of twenty children. *J. Clin. Diagnostic Res*. 9: SC09-SC12.
- M. Hussein, L., H. Ali, S., H. Mohammed, N., 2017. Electrophysiological evaluation of Guillain–Barre syndrome subtypes in childhood. *J. Fac. Med*. 59: 60–64.
- Mitsui, Y., Kusunoki, S., Arimura, K., Kaji, R., Kanda, T., Kuwabara, S., *et al.*, 2015. A multicentre prospective study of Guillain-Barré Syndrome in Japan: A focus on the incidence of subtypes. *J. Neurol. Neurosurg. Psychiatry* 86: 110–114.
- Rajabally, Y.A., Uncini, A., 2012. Outcome and its predictors in Guillaine-Barré syndrome. *J. Neurol. Neurosurg. Psychiatry* 83: 711–718.
- Roodbol, J., de Wit, M.C.Y., van den Berg, B., Kahlmann, V., Drenthen, J., Catsman-Berrevoets, C.E., *et al.*, 2017. Diagnosis of Guillain–Barré syndrome in children and validation of the Brighton criteria. *J. Neurol*. 264: 856–861.
- Sung, E.J., Kim, D.Y., Chang, M.C., Ko, E.J., 2016. Prediction of functional outcome in axonal guillain-barre syndrome. *Ann. Rehabil. Med*. 40: 481–488.
- Tan, C., Razali, S.N.O., Nortina, K.G., 2019. The utility of Guillain-Barré syndrome prognostic models in Malaysian patients. *J Peripher Nerv Syst*. 24 :168–173.
- van Doorn, P.A., Ruts, L., Jacobs, B.C., 2008. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. *Lancet Neurol*. 7: 939–50.
- Verboon, C., Van Doorn, P.A., Jacobs, B.C., 2017. Treatment dilemmas in Guillain-Barré syndrome. *J. Neurol. Neurosurg. Psychiatry* 88: 346–52.
- Wakerley, B.R., Uncini, A., Yuki, N., 2014. Guillain-Barré and miller fisher syndromes - New diagnostic classification. *Nat. Rev. Neurol*. 10: 537–44.
- Walgaard, C., 2011. Early recognition of poor prognosis in Guillain-Barre syndrome. *Neurol*. 76:968-975.
- Willison, H.J., Jacobs, B.C., Doorn, P.A. Van, 2016. Guillain-Barré syndrome. *Lancet*. 388: 717–27.
- Zhang, B., Wu, X., Shen, D., Li, T., Li, C., Mao., *et al.*, 2017. The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome. *Med. (United States)* 96: 1–6.

Ziganshin, R.H., Ivanova, O.M., Lomakin, Y.A., Belogurov, A.A., Kovalchuk, S.I., Azarkin, I. V., *et al.*, 2016. The pathogenesis of the demyelinating form of guillain-barre syndrome (GBS): Proteopeptidomic and immunological profiling of physiological fluids. *Mol. Cell. Proteomics* 15: 2366–2378.